Table 2. Main criticisms reported with first-generation EGFR-TKIs.
| No response in near 30% of NSCLC with classical exon 19-21 mutation |
| No clear benefit in presence of uncommon mutations |
| Toxicity |
| No patient is cured: median duration of response 9-12 months |
| Lack of efficacy in presence of “acquired” T790M mutation |